NDC 67184-0549-01 - Daptomycin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67184-0549
- Requested NDC
- 67184-0549-01
- Package NDCs from labels
- 67184-0549-1, 67184-0549-01
- Manufacturer
- Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd.
- Effective date
- 2025-06-16
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Daptomycin | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd. | 2025-06-16 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67184-0549-1 | Daptomycin | 10 mL in 1 VIAL, SINGLE-USE | INJECTION, POWDER, LYOPHILIZED, | 10 | 6 | |
| 67184-0549-1 | Daptomycin | 1 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 1 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 67184-0549 | DAPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [QILU PHARMACEUTICAL CO., LTD.] | 4 | Current NDC, Legacy NDC, 2 package rows | 20211118_e32c7141-fbd9-47c8-bd1e-94b880b2c5a6.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| daptomycin | DAPTOMYCIN | Slate Run Pharmaceuticals, LLC | 3890474a-4425-43b3-97d4-5370cc35c2f7 | 2022-10-01 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Fresenius Kabi USA, LLC | a990141d-7b92-48a5-a41d-1254522e2aa1 | 2022-06-09 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| daptomycin | DAPTOMYCIN | Sagent Pharmaceuticals | f4ad8613-f25e-4b82-9621-cc5ff9525d3e | 2022-05-17 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Hikma Pharmaceuticals USA Inc. | 1a7c9f52-7b58-49e9-93d7-5a26a7d1ef09 | 2022-04-29 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| DAPZURA RT | DAPTOMYCIN | Baxter Healthcare Corporation | cb1283e1-35b8-425c-b338-d9ac0c7161f8 | 2022-01-25 | Warnings, Adverse reactions | 403920 NWQ5N31VKK |
| Daptomycin | DAPTOMYCIN | Dr. Reddy's Laboratories Inc., | d750e28d-1353-4671-66a3-ea4e49e81e7b | 2021-10-04 | Warnings, Adverse reactions | NWQ5N31VKK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.